Evidence map›Paper›PMID 25474103›Full record

Trial reportPLoS pathogens2014

Oral streptococci utilize a Siglec-like domain of serine-rich repeat adhesins to preferentially target platelet sialoglycans in human blood.

Lingquan Deng, Barbara A Bensing, Supaporn Thamadilok, Hai Yu, Kam Lau, Xi Chen, Stefan Ruhl, Paul M Sullam, Ajit Varki

Open access · goldAbstract readClinical Trial
In one paragraph

Trial report in PLoS pathogens, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed
5.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

60 citing papers in PubMed, 90 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Oral streptococci: modulators of health and disease.Frontiers in cellular and infection microbiology · 2024
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Frontiers in cellular and infection microbiology · 2022
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Lingquan DengGlycobiology Research and Training Center, Departments of Medicine and Cellular & Molecular Medicine, University of California, San Diego, San Diego, California, United States of America.
Barbara A BensingDepartment of Medicine, San Francisco Veterans Affairs Medical Center and the University of California, San Francisco, San Francisco, California, United States of America.
Supaporn ThamadilokDepartment of Oral Biology, School of Dental Medicine, University at Buffalo, Buffalo, New York, United States of America.
Hai YuDepartment of Chemistry, University of California, Davis, Davis, California, United States of America.
Kam LauDepartment of Chemistry, University of California, Davis, Davis, California, United States of America.
Xi ChenDepartment of Chemistry, University of California, Davis, Davis, California, United States of America.
Stefan RuhlDepartment of Oral Biology, School of Dental Medicine, University at Buffalo, Buffalo, New York, United States of America.
Paul M SullamDepartment of Medicine, San Francisco Veterans Affairs Medical Center and the University of California, San Francisco, San Francisco, California, United States of America.
Ajit VarkiGlycobiology Research and Training Center, Departments of Medicine and Cellular & Molecular Medicine, University of California, San Diego, San Diego, California, United States of America.
University of California, Davis · USUniversity at Buffalo, State University of New York · USUniversity of California, San Diego · USSan Francisco VA Medical Center · USUniversity of California, San Francisco · US

Funding

Siglec Modulation of Inflammatory ResponsesP01HL107150 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI VARKI, NISSI MARY · 2011 to 2017
$18.0M
STREPTOCOCCAL PLATELET BINDING AND ENDOCARDITISR01AI041513 · NIAID · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI SULLAM, PAUL M. · 1997 to 2019
$5.6M
Microbial Recognition of Sialic Acid Diversity in the Salivary ProteomeR01DE019807 · NIDCR · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI RUHL, STEFAN HANS-KLAUS · 2010 to 2022
$4.7M
Mechanisms for ligand binding by serine-rich adhesins of Gram-positive pathogensR01AI106987 · NIAID · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI IVERSON, T M, SULLAM, PAUL M. · 2014 to 2018
$3.4M
Oligosaccharides as antimicrobials and prebioticsR01HD065122 · NICHD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI CHEN, XI · 2010 to 2013
$1.8M
The accessory Sec system of Gram-positive pathogensI01BX001653 · VA · VETERANS AFFAIRS MED CTR SAN FRANCISCO · PI SULLAM, PAUL M. · 2013 to 2016
–
BLRD VA I01 BX001653NHLBI NIH HHS NIH P01HL107150NHLBI NIH HHS P01 HL107150NIAID NIH HHS R01 AI041513NIAID NIH HHS R01 AI106987NIAID NIH HHS R01-AI106987NIAID NIH HHS R01-AI41513NICHD NIH HHS R01 HD065122NICHD NIH HHS R01HD065122NIDCR NIH HHS NIH/NIDCR DE019807NIDCR NIH HHS R01 DE019807
6 · The paper itself

Abstract

Damaged cardiac valves attract blood-borne bacteria, and infective endocarditis is often caused by viridans group streptococci. While such bacteria use multiple adhesins to maintain their normal oral commensal state, recognition of platelet sialoglycans provides an intermediary for binding to damaged valvular endocardium. We use a customized sialoglycan microarray to explore the varied binding properties of phylogenetically related serine-rich repeat adhesins, the GspB, Hsa, and SrpA homologs from Streptococcus gordonii and Streptococcus sanguinis species, which belong to a highly conserved family of glycoproteins that contribute to virulence for a broad range of Gram-positive pathogens. Binding profiles of recombinant soluble homologs containing novel sialic acid-recognizing Siglec-like domains correlate well with binding of corresponding whole bacteria to arrays. These bacteria show multiple modes of glycan, protein, or divalent cation-dependent binding to synthetic glycoconjugates and isolated glycoproteins in vitro. However, endogenous asialoglycan-recognizing clearance receptors are known to ensure that only fully sialylated glycans dominate in the endovascular system, wherein we find these particular streptococci become primarily dependent on their Siglec-like adhesins for glycan-mediated recognition events. Remarkably, despite an excess of alternate sialoglycan ligands in cellular and soluble blood components, these adhesins selectively target intact bacteria to sialylated ligands on platelets, within human whole blood. These preferred interactions are inhibited by corresponding recombinant soluble adhesins, which also preferentially recognize platelets. Our data indicate that circulating platelets may act as inadvertent Trojan horse carriers of oral streptococci to the site of damaged endocardium, and provide an explanation why it is that among innumerable microbes that gain occasional access to the bloodstream, certain viridans group streptococci have a selective advantage in colonizing damaged cardiac valves and cause infective endocarditis.

Indexed as

Adhesins, BacterialBlood PlateletsEndocarditis, BacterialFemaleHumansMaleProtein Array AnalysisSialic Acid Binding Immunoglobulin-like LectinsStreptococcus gordoniiStreptococcus sanguisVirulence FactorsAdhesins, BacterialSialic Acid Binding Immunoglobulin-like LectinsVirulence Factors

Identifiers

PMID25474103
PMCPMC4256463
OpenAlexW2102779260

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.